Home › Waldenstrom Macroglobulinemia › New Jersey
Waldenstrom Macroglobulinemia clinical trials in New Jersey
7 studies for Waldenstrom Macroglobulinemia are looking for participants at sites in New Jersey.
Cities in New Jersey
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memoral Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07231952Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04840602Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Astera Cancer Care ( Site 2732), East Brunswick
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704), Hackensack
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04728893A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Rutgers Cancer Institute of New Jersey, New Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START New Jersey, East Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07424833SynKIR-310 for Relapsed/Refractory B-NHL
- Rutgers Cancer Institute, New Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT06544265Study of SGR-1505 in Mature B-Cell Neoplasms
- Regional Cancer Care Associates, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.